Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Inimex Pharmaceuticals

Request full access

Innate Defense Regulator drugs for infections, tissue injury

Burnaby, CanadaFounded 2001Biotech & Life Sciences

About Inimex Pharmaceuticals

Inimex Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing a novel class of drugs called Innate Defense Regulators (IDRs) to combat infections and manage tissue injury. The company was founded in 2001 by Brett Finlay and R. Hancock, professors from the University of British Columbia, based on their research into immune system modulators. The firm's stated mission was the discovery, development, and commercialization of new medicines that selectively modulate the body's innate immune response.

The company's core technology centered on IDRs, which are small, synthetic peptides designed to trigger the body's innate defenses without causing harmful inflammation. Unlike traditional antibiotics that target bacteria directly, IDRs work by modulating host pathways, specifically by binding to the intracellular adaptor protein p62. This mechanism enhances the body's ability to clear a broad spectrum of pathogens, including antibiotic-resistant strains, and control inflammation, offering potential advantages where conventional antibiotics fail. The lead drug candidate, IMX942 (later SGX942), was developed to treat infections and conditions involving tissue injury, such as ventilator-associated pneumonia, cancer-related mucositis, and infections in chemotherapy patients.

Inimex successfully raised a total of $28 million over three funding rounds. A significant Series B financing round in June 2008 raised US$22 million, led by investors including Morningside Venture Investments, Roche Venture Fund, and Astellas Venture Management. This funding was crucial for advancing IMX942 into clinical trials. The first-in-human Phase 1 safety study of IMX942 began in April 2009. By 2010, the company had successfully completed Phase 1 studies and was planning Phase 2 trials. However, multiple sources indicate that Inimex Pharmaceuticals is now closed or archived.

Source: Dealroom company data

At a glance

Status
Closed
Employees
2
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2C

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Dec 2010 $240K — State Small Business Credit Initiative —
SERIES B✓Equity / VC Jun 2008 $22M $88M Astellas Venture · Morningside —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Inimex Pharmaceuticals team growth

Inimex Pharmaceuticals's team grew 0% over the past year.

1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Inimex Pharmaceuticals in the Burnaby ecosystem

Live from Dealroom

The Inimex Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • State Small Business Credit Initiative

Series A4 investors entered at this stage

  • British Columbia Discovery Fund
  • GrowthWorks Capital
  • Morningside
  • Astellas Venture

Other known investors4 additional known investors

  • The University of British Columbia
  • BDC Capital
  • Canadian Medical Discoveries Fund
  • MDS Capital
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇦 Canada · Burnaby HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Inimex Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Inimex Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.